Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Merck also lowered revenue guidance for 2025. 10 stocks we like better than Merck › The stock for pharmaceutical giant Merck ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

Last week’s earnings call didn’t deliver what Merck & Co. ($MRK) investors were hoping for. While the company posted what ...

Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock ...

Q3 earnings beat estimates, but shares dip as 2025 sales outlook narrows. Get key highlights and pharma market insights.

Merck & Co. is taking full control of MK-8690, an investigational drug targeting inflammatory bowel diseases that was part of the drugmaker's $10.8 billion acquisition of Prometheus Biosciences in ...

Merck & Co Inc. (NYSE:MRK) is one of the best stocks to invest in, according to billionaire D.E. Shaw. On October 30, Merck & Co Inc.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...